ANI Pharmaceuticals EV/EBIT ANIP

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2013.

Today, Oct 23, 2026: 10.5×
10-year median: 25.9×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 10.1× to 214×
Peer median: 8.5×

ANI Pharmaceuticals' EV/EBIT is 10.5× as of Oct 23, 2026.

That is below its ten-year median of 25.9×, lower than on 99% of days in the last ten years.

Over that time it ranged from 10.1× in Sep 2026 to 214× in May 2025.

The median for 10 large drugmakers of a similar size is 8.5×.

EV/EBIT over time

median 25.9×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.5×	10.1×	24.4×
2025	23.7×	22.9×	214×
2024	112×	22.2×	125×
2023	27.2×	24.4×	62.2×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	53.1×	20.1×	58.9×
2019	21.6×	18.1×	30.3×
2018	16.3×	15.4×	32.9×
2017	29.7×	18.8×	34.3×
2016	32.1×	8.0×	35.3×
2015	13.0×	11.4×	58.5×
2014	45.9×	25.1×	80.6×
2013	40.9×	13.7×	40.9×

Against its peers

Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
ANIPANI Pharmaceuticals	10.5×
PAHCPhibro Animal Health	11.7×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	7.6×
HRMYHarmony Biosciences	6.9×
PBHPrestige Consumer Healthcare	14.5×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	12.2×
NRIXNurix Therapeutics	7.1×
ABUSArbutus Biopharma	4.9×
OGNOrganon	9.5×
Peer median	8.5×

Where ANI Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on ANI Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.